RxDoctor Payments Data

Sherron Miller, APRN

Psychiatric/Mental Health · Hollywood, FLNPI 1922352905

Payments from drug & device makers

$8,313in general payments, 2019–2025

Across 330 payments — averaging $25.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Alkermes, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Neurocrine Biosciences, Inc.$908
  • AbbVie$776
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$8,305100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,313 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$24,563
Medicare patients
115
Services billed
321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate56$156,877
VraylarCariprazine Hcl98$143,153
AustedoDeutetrabenazine17$139,339
Austedo XrDeutetrabenazine15$76,927
Abilify MaintenaAripiprazole26$63,580
RexultiBrexpiprazole36$60,291
Aripiprazole241$25,650
SaphrisAsenapine Maleate11$6,853
Quetiapine Fumarate323$4,875
Lurasidone Hcl30$4,290
Paliperidone ErPaliperidone24$3,152
Doxepin Hcl159$3,142
Divalproex Sodium ErDivalproex Sodium75$2,611
Clonazepam281$2,171
Ziprasidone Hcl42$1,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$1,066$216,26532 claims
Johnson & JohnsonInvega Sustenna$1,691$156,87756 claims
AbbVieVraylar, Saphris$776$150,006109 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$613$123,87162 claims
Almatica Pharma LLCSertraline Hcl$24$823189 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →